Avalo Therapeutics Inc (AVTX) — Cash Flow Quality Index

Latest as of September 2024: -0.50x

Avalo Therapeutics Inc (AVTX) has a Cash Flow Quality Index of -0.50x as of September 2024. Operating cash flow of $-11.53 Million is below net income of $23.04 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash flow to debt ratio of Avalo Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-0.50x
Operating CF / Net Income

Operating Cash Flow

$-11.53 Million
USD

Net Income

$23.04 Million
USD

Data as of

Sep 2024
Most recent filing

Avalo Therapeutics Inc Cash Flow Quality Index (2017–2017)

Historical Cash Flow Quality Index for Avalo Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see AVTX operating cash flow.

Annual Cash Flow Quality Index for Avalo Therapeutics Inc (2017–2017)

Year-by-year earnings quality comparison for Avalo Therapeutics Inc.

Year Quality Index Operating CF (USD) Net Income YoY Change
2017 1.05x $12.52 Million $11.87 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.